A factual, citation-backed look at how 5-Amino-1MQ has been used in published research — and what that means for dosing protocols.
Last reviewed: August 2026 | Written by the True Ability Labs Research Team | All claims cited to peer-reviewed sources below.
What Is 5-Amino-1MQ?
5-Amino-1MQ (5-amino-1-methylquinolinium) is a selective, cell-permeable small-molecule inhibitor of NNMT (nicotinamide N-methyltransferase) — an enzyme expressed primarily in adipose tissue and liver that regulates NAD+ biosynthesis and the cellular methylation cycle [1].
It was first characterised as a potent NNMT inhibitor by Neelakantan et al. (2018) at the University of Texas, where it demonstrated the ability to cross cell membranes and inhibit NNMT activity with high selectivity [1]. It is not a peptide, not a hormone, and not a stimulant. It is a research compound supplied for investigational purposes only.
For a full explainer on NNMT and why inhibiting it is an active area of metabolic research, see: 5-Amino-1MQ: The NNMT Inhibitor Redefining Metabolic Research in 2026.
Dosage Used in Published Research
The primary published study on 5-Amino-1MQ in vivo is Neelakantan et al. (2018), published in Biochemical Pharmacology. In this study, mice on a high-fat diet were administered 5-Amino-1MQ orally. The compound was associated with reduced weight gain and improved metabolic markers compared to controls, with no observed hepatotoxicity at the doses tested [1].
Key parameters from the published research:
- Administration route: oral (consistent with capsule delivery)
- Dosing frequency: daily administration in the animal model
- Duration: multi-week protocol
- Outcome markers monitored: body weight, adipose tissue mass, NAD+ levels, liver enzyme panels [1]
Important limitation: This research was conducted in murine (mouse) models. No peer-reviewed human clinical trials for 5-Amino-1MQ have been published to date. Human dosing cannot be directly extrapolated from animal data without clinical validation.
The 50mg Reference Dose
True Ability Labs formulates 5-Amino-1MQ at 50mg per capsule. This reflects the dosage range most commonly referenced in current research literature and researcher community discussions. Each capsule contains a single, accurately measured dose — no fillers, no binders, no underdosing.
The 50mg dose is consistent with the molecular weight and potency profile of 5-Amino-1MQ as characterised in the Neelakantan et al. study, where the compound demonstrated NNMT inhibitory activity at low concentrations [1].
What Researchers Typically Consider
When designing protocols involving NNMT inhibitors, researchers in the published literature and investigational community generally account for:
- Starting dose: beginning at the lowest dose with documented activity in the literature
- Administration frequency: daily dosing is the most common protocol in published animal studies [1]
- Cycling: on/off cycles are used in some investigational protocols to assess baseline recovery and avoid receptor adaptation — though no published cycling data exists specifically for 5-Amino-1MQ
- Biomarker monitoring: NAD+ levels, metabolic markers, and liver function panels are the primary endpoints tracked in published NNMT inhibitor research [2, 1]
NNMT, NAD+, and Why Dosing Precision Matters
NNMT inhibition works by reducing the enzymatic consumption of nicotinamide — a direct NAD+ precursor. Elevated NNMT activity depletes both nicotinamide and SAM (S-adenosylmethionine), disrupting NAD+ biosynthesis and the broader methylation cycle [2].
Because the mechanism operates at the enzymatic level, dose accuracy matters more than with many other research compounds. An underdosed capsule may not achieve meaningful NNMT inhibition; an overdosed one introduces unnecessary variables. This is why label accuracy and third-party testing are non-negotiable for serious researchers — see our NNMT Inhibitor Buyer's Guide for what to look for when sourcing.
Important Considerations
- 5-Amino-1MQ is a research compound. It is not approved by the MHRA or FDA for human therapeutic use
- Published human clinical trial data does not currently exist for this compound
- Long-term human safety data is not established
- Always consult a qualified healthcare professional before use
- This article is for informational and research purposes only and does not constitute medical advice
Shop 5-Amino-1MQ 50mg
→ 5-Amino-1MQ 50mg | 60 Capsules
Have questions? Visit our FAQ page.
References
- Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology. 2018;147:141–152. PubMed: 30257040
- Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508(7495):258–262. PubMed: 23604011
Food supplement. Not a medicine. Not intended to diagnose, treat, cure, or prevent any disease. For research purposes only. Always consult a qualified healthcare professional before use.
